DaVita Stock Surges as 2024 Outlook Outpaces Wall Street Estimates

Shares of the Denver-based healthcare giant rose 12% to $124.06 in pre-market activity. The rally provides a significant boost to a valuation that had retreated 37% over the last twelve months. Investors reacted favorably to a report that demonstrated both top-line growth and disciplined cost management in a challenging labor environment.

For the final quarter of the year, DaVita reported adjusted earnings of $3.40 per share, exceeding the $3.24 per share expected by analysts polled by FactSet. Revenue rose to $3.62 billion, up from $3.29 billion in the prior-year period. This performance was driven by increased patient service revenue and steady demand for dialysis services.

Strengthening the 2024 Forecast

The company’s forward-looking statements provided the primary catalyst for the stock’s double-digit gain. DaVita now expects full-year adjusted earnings to land between $13.60 and $15.00 per share, a range that sits well above the $12.82 consensus estimate held by Wall Street prior to the release.

The provider’s financial targets for the coming year highlight a robust cash position and operational stability. According to the company's financial report, DaVita is projecting:

• Adjusted operating income between $2.09 billion and $2.24 billion.
• Free cash flow ranging from $1 billion to $1.25 billion.
• A continued emphasis on operational efficiency to offset inflationary pressures.

While net profit for the quarter sat at $234.2 million—a slight dip from the $259.3 million reported a year earlier—the rise in earnings per share to $3.29 reflects the impact of the company's aggressive share repurchase programs.